EU Expert Panel Recommends Lilly’s Foundayo Weight-Loss Pill

An expert panel advising the European Union’s drug regulator recommended marketing authorization for Eli Lilly and Company’s Foundayo, moving the company’s oral weight-loss medicine closer to possible approval in Europe. Foundayo, which contains orforglipron, is a pill. The endorsement advances Lilly’s position in a market where rival Novo has the first-mover advantage. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.